These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 7432418)

  • 41. The randomized clinical trial: bias in analysis.
    May GS; DeMets DL; Friedman LM; Furberg C; Passamani E
    Circulation; 1981 Oct; 64(4):669-73. PubMed ID: 7023743
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of platelet-active drugs in coronary artery disease.
    Sherry S
    Cardiovasc Clin; 1983; 14(1):173-89. PubMed ID: 6352025
    [No Abstract]   [Full Text] [Related]  

  • 43. Sulphinpyrazone in the prevention of cardiac death after myocardial infarction.
    S Afr Med J; 1980 Mar; 57(9):301-2. PubMed ID: 6986664
    [No Abstract]   [Full Text] [Related]  

  • 44. Reduction in the severity of myocardial infarction by sulfinpyrazone.
    Innes IR; Weisman H
    Am Heart J; 1981 Aug; 102(2):153-7. PubMed ID: 7258086
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of acute and long-term beta-adrenergic blockade with alprenolol in definite or suspected myocardial infarction. Study design, patient characteristics and conduct of the study.
    Jürgensen HJ; Andersen MP; Bechsgaard P; Frederiksen J; Hansen DA; Nielsen PB; Pedersen F; Pedersen-Bjergaard O; Rasmussen SL
    Acta Med Scand Suppl; 1984; 680():8-17. PubMed ID: 6375283
    [No Abstract]   [Full Text] [Related]  

  • 46. New job for an old drug?
    Relman AS
    N Engl J Med; 1978 Feb; 298(6):333-4. PubMed ID: 622092
    [No Abstract]   [Full Text] [Related]  

  • 47. Weighing benefits and risks--the FDA's review of prasugrel.
    Unger EF
    N Engl J Med; 2009 Sep; 361(10):942-5. PubMed ID: 19726770
    [No Abstract]   [Full Text] [Related]  

  • 48. Summary of design features: clinical trials of platelet-active drugs in cerebrovascular disease.
    Friedman LM
    Circulation; 1980 Dec; 62(6 Pt 2):V88-9. PubMed ID: 7002355
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Trials of antiplatelet drugs: some methodological considerations.
    Armitage P
    Rev Epidemiol Sante Publique; 1979 Sep; 27(2):87-90. PubMed ID: 538303
    [No Abstract]   [Full Text] [Related]  

  • 50. [Various observations on the results of the "Aspirin myocardial infarction study" and the "Persantine-aspirin reinfarction study" in the United States].
    Lubsen J
    Ned Tijdschr Geneeskd; 1981 Oct; 125(40):1606-9. PubMed ID: 7029311
    [No Abstract]   [Full Text] [Related]  

  • 51. Improved prognosis during long-term treatment with beta-blockers after myocardial infarction: analysis of randomized trials and pooling of results.
    Bassan MM; Shalev O; Eliakim A
    Heart Lung; 1984 Mar; 13(2):164-8. PubMed ID: 6142030
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Protocol design.
    Wilensky AJ
    Epilepsy Res Suppl; 1993; 10():107-13. PubMed ID: 8251086
    [No Abstract]   [Full Text] [Related]  

  • 53. Propranolol therapy in patients with acute myocardial infarction: the Beta-Blocker Heart Attack Trial.
    Goldstein S
    Circulation; 1983 Jun; 67(6 Pt 2):I53-7. PubMed ID: 6342840
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug markers questioned.
    Ledford H
    Nature; 2008 Apr; 452(7187):510-1. PubMed ID: 18385695
    [No Abstract]   [Full Text] [Related]  

  • 55. Shortcomings of the National Crohn's Disease Study: the exclusion of azathioprine without adequate trial.
    Korelitz BI; Present DH
    Gastroenterology; 1981 Jan; 80(1):193-6. PubMed ID: 6108892
    [No Abstract]   [Full Text] [Related]  

  • 56. FDA explores new antiretroviral trial designs: interview with David Feigal, M.D. Interview by John S. James.
    Feigal D
    AIDS Treat News; 1997 Jun; (No 273):1-5. PubMed ID: 11364399
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A controlled trial of sotalol for 1 year after myocardial infarction.
    Julian DG; Jackson FS; Szekely P; Prescott RJ
    Circulation; 1983 Jun; 67(6 Pt 2):I61-2. PubMed ID: 6342842
    [TBL] [Abstract][Full Text] [Related]  

  • 58. E.P.S.I.M., the French oral anticoagulant--aspirin trial in post-myocardial infarction patients: design, organization and quality control procedures.
    Boissel JP; Leizorovicz A; Schbath J; Destors JM; Gillet J
    Scand J Haematol Suppl; 1981; 38():47-72. PubMed ID: 7038857
    [No Abstract]   [Full Text] [Related]  

  • 59. Anturan: new use for an old drug.
    Can Med Assoc J; 1980 Mar; 122(6):714-6. PubMed ID: 6988068
    [No Abstract]   [Full Text] [Related]  

  • 60. Secondary prevention of death and reinfarction with verapamil after an acute myocardial infarction. The Danish Study Group on Verapamil in Myocardial Infarction.
    J Hum Hypertens; 1990 Dec; 4 Suppl 5():19-25. PubMed ID: 2090834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.